Joel Raskin

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc The effect of initial duloxetine dosing strategy on nausea in korean patients with major depressive disorder
    Min Soo Lee
    Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea
    Psychiatry Investig 9:391-9. 2012
  2. doi request reprint Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Ave, Toronto, ON, Canada M1N 2E8
    J Psychiatr Res 46:667-74. 2012
  3. ncbi request reprint Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Canada
    Pain Med 7:373-85. 2006
  4. ncbi request reprint Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
    Int Psychogeriatr 20:309-27. 2008
  5. ncbi request reprint Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain
    Joel Raskin
    Lilly Research Laboratories, Toronto, Canada
    J Palliat Med 9:29-40. 2006
  6. ncbi request reprint Duloxetine in the long-term treatment of major depressive disorder
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Avenue, Scarborough, Ontario, Canada M1N 2E8
    J Clin Psychiatry 64:1237-44. 2003
  7. ncbi request reprint A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
    Pain Med 6:346-56. 2005
  8. doi request reprint Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
    J Clin Psychopharmacol 28:32-8. 2008
  9. ncbi request reprint Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Ave, Toronto, Ontario, Canada MIN 2E8
    Am J Psychiatry 164:900-9. 2007
  10. ncbi request reprint An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Med 8:503-13. 2007

Detail Information

Publications28

  1. pmc The effect of initial duloxetine dosing strategy on nausea in korean patients with major depressive disorder
    Min Soo Lee
    Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea
    Psychiatry Investig 9:391-9. 2012
    ..To assess the relative severity of nausea in patients from Korea with major depressive disorder (MDD) who were treated with duloxetine at low (30 mg) or high (60 mg) doses, with or without food, for the first week of an 8 week treatment...
  2. doi request reprint Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Ave, Toronto, ON, Canada M1N 2E8
    J Psychiatr Res 46:667-74. 2012
    ..However, given the study limitations, it is possible that more specific targeting of the noradrenergic pathway would be of benefit...
  3. ncbi request reprint Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Canada
    Pain Med 7:373-85. 2006
    ..This study assessed the 6-month safety and tolerability of duloxetine in patients with DPNP; evaluation of efficacy was a secondary objective...
  4. ncbi request reprint Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
    Int Psychogeriatr 20:309-27. 2008
    ..Rapid response to antidepressant therapy is desirable and may be particularly critical in elderly patients with major depressive disorder (MDD)...
  5. ncbi request reprint Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain
    Joel Raskin
    Lilly Research Laboratories, Toronto, Canada
    J Palliat Med 9:29-40. 2006
    ....
  6. ncbi request reprint Duloxetine in the long-term treatment of major depressive disorder
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Avenue, Scarborough, Ontario, Canada M1N 2E8
    J Clin Psychiatry 64:1237-44. 2003
    ..This clinical trial evaluated the long-term (1 year) safety and efficacy of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, in patients with DSM-IV major depressive disorder...
  7. ncbi request reprint A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
    Pain Med 6:346-56. 2005
    ..Assess efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, on the reduction of pain severity, in patients with diabetic peripheral neuropathic pain (DPNP)...
  8. doi request reprint Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
    J Clin Psychopharmacol 28:32-8. 2008
    ..To compare the safety and tolerability profile of duloxetine versus placebo in elderly (> or = 65 years) patients with major depressive disorder (MDD)...
  9. ncbi request reprint Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Ave, Toronto, Ontario, Canada MIN 2E8
    Am J Psychiatry 164:900-9. 2007
    ..This study compared the effects of duloxetine, 60 mg/day, versus placebo on cognition, depression, and pain in elderly patients with recurrent major depressive disorder...
  10. ncbi request reprint An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Med 8:503-13. 2007
    ..To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare duloxetine with routine care in the management of patients with diabetic peripheral neuropathic pain (DPNP)...
  11. ncbi request reprint An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Saf 30:437-55. 2007
    ..This study was designed to evaluate the cardiovascular safety profile of the SNRI duloxetine through evaluation of cardiovascular-related parameters and adverse events (AEs)...
  12. ncbi request reprint A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder
    David G S Perahia
    Lilly Research Centre, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    J Psychiatr Res 42:22-34. 2008
    ..The objective was to compare the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine using GBR assessment...
  13. doi request reprint Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis
    Madelaine M Wohlreich
    correspondence and M D, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4103, Indianapolis, IN 46285, USA
    Psychosomatics 50:402-12. 2009
    ....
  14. pmc The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    BMC Psychiatry 4:26. 2004
    ..We compared results from MMRM and LOCF_ANCOVA analyses across eight clinical trials of duloxetine in order to investigate how the choice of primary analysis may influence interpretations of efficacy...
  15. ncbi request reprint Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics
    David G S Perahia
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 21:285-95. 2006
    ..Duloxetine was effective in the treatment of first and subsequent episodes of major depressive disorder, and regardless of duration of the current depressive episode...
  16. pmc Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features
    Craig H Mallinckrodt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    BMC Psychiatry 5:1. 2005
    ..Pooled data from double-blind, placebo-controlled studies were utilized to compare the efficacy of duloxetine in depressed patients with and without melancholic features...
  17. ncbi request reprint Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
    David G S Perahia
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 21:311-7. 2006
    ....
  18. doi request reprint Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies
    Tina M Oakes
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Int Clin Psychopharmacol 28:1-11. 2013
    ..The incidence of abnormal low sodium levels was not significantly different between treatments. These safety results may better inform clinicians providing individualized care to elderly patients with major depressive disorder...
  19. ncbi request reprint Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects
    Sidney H Kennedy
    Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 63:181-6. 2002
    ....
  20. ncbi request reprint Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials
    Christer Allgulander
    Karolinska Institutet, Stockholm, Sweden
    Curr Med Res Opin 23:1245-52. 2007
    ..A pooled dataset from all completed trials is provided here to show the most likely clinical outcomes associated with duloxetine treatment for GAD...
  21. ncbi request reprint Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine
    John Greist
    Healthcare Technology Systems, Madison, Wisconsin 53717, USA
    Clin Ther 26:1446-55. 2004
    ..This analysis assessed the incidence, severity, onset, and duration of nausea among patients with major depressive disorder (MDD) treated with the new antidepressant duloxetine...
  22. ncbi request reprint Management of depression relapse: re-initiation of duloxetine treatment or dose increase
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, ACC 812, Boston, MA 02114, United States
    J Psychiatr Res 40:328-36. 2006
    ..Patients relapsing on duloxetine 60 mg QD benefited from an increase to 60 mg BID. These duloxetine doses were well tolerated and effective, and appear appropriate for MDD patients requiring treatment of relapse...
  23. ncbi request reprint Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial
    Moira Rynn
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Depress Anxiety 25:182-9. 2008
    ..Duloxetine was an efficacious, safe, and well-tolerated treatment that resulted in clinically significant improvements in symptom severity and functioning for patients with GAD...
  24. doi request reprint Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies
    Jonathan Davidson
    Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    Hum Psychopharmacol 23:519-26. 2008
    ..To assess the efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder (GAD)...
  25. ncbi request reprint Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial
    Stephan Brecht
    Boehringer Ingelheim GmbH, Ingelheim, Germany
    J Clin Psychiatry 68:1707-16. 2007
    ..This study evaluated the efficacy and safety of duloxetine in the treatment of patients with moderate pain associated with depression...
  26. ncbi request reprint Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Int Clin Psychopharmacol 22:348-55. 2007
    ....
  27. ncbi request reprint Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies
    Jean Endicott
    New York State Psychiatric Institute and Columbia School of Medicine, New York, NY 10032, USA
    J Clin Psychiatry 68:518-24. 2007
    ..The present work examined the efficacy of duloxetine treatment for improving functional outcomes for patients with GAD in 3 independent clinical studies...
  28. ncbi request reprint Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil
    Phil Lee
    Eli Lilly, Taipei, Taiwan
    Psychiatry Clin Neurosci 61:295-307. 2007
    ..The present study verifies the utility of duloxetine as an efficacious and safe treatment for both emotional and physical symptoms of MDD in this predominantly Asian patient sample...